Why SSY Group (SEHK:2005) Is Up 6.6% After NMPA Clears New Hypertension Combo Therapy

Simply Wall St.01-09

SSY Group Limited recently announced that it obtained National Medical Products Administration approval in China for its Perindopril Arginine and Amlodipine Besylate Tablets (III), a type 4 chemical ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602308467?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-01-09 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602308467","market":"us","top_or_hot":-1,"title":"Why SSY Group (SEHK:2005) Is Up 6.6% After NMPA Clears New Hypertension Combo Therapy","media":"Simply Wall St.","content":"<div>\n<p>SSY Group Limited recently announced that it obtained National Medical Products Administration approval in China for its Perindopril Arginine and Amlodipine Besylate Tablets (III), a type 4 chemical ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/why-ssy-group-sehk2005-is-up-66-after-nmpa-clears-new-hypert\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why SSY Group (SEHK:2005) Is Up 6.6% After NMPA Clears New Hypertension Combo Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy SSY Group (SEHK:2005) Is Up 6.6% After NMPA Clears New Hypertension Combo Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/why-ssy-group-sehk2005-is-up-66-after-nmpa-clears-new-hypert><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SSY Group Limited recently announced that it obtained National Medical Products Administration approval in China for its Perindopril Arginine and Amlodipine Besylate Tablets (III), a type 4 chemical ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/why-ssy-group-sehk2005-is-up-66-after-nmpa-clears-new-hypert\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSY","symbol_name":"Sunlink Health Systems Inc","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/why-ssy-group-sehk2005-is-up-66-after-nmpa-clears-new-hypert","article_id":"2602308467","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2005/ssy-group-shares/news/why-ssy-group-sehk2005-is-up-66-after-nmpa-clears-new-hypert","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602308467","pubTimestamp":1767958181,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSY Group Limited recently announced that it obtained National Medical Products Administration approval in China for its Perindopril Arginine and Amlodipine Besylate Tablets (III), a type 4 chemical drug for adult hypertension patients whose blood pressure is not adequately controlled by monotherapy.\nThis regulatory clearance, which includes passing the consistency evaluation, adds a new fixed-dose combination hypertension therapy to SSY Group’s pharmaceutical portfolio and broadens its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"SSY":"Sunlink Health Systems Inc","III":"信息服务","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团","BK4134":"信息科技咨询与其它服务","BK4185":"保健护理机构","BK1191":"制药"},"translate_title":"为什么SSY Group(SEHK：2005)在NMPA批准新的高血压组合疗法后上涨6.6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SSY":1.5,"02005":0.9,"III":1},"content_text":"SSY Group Limited recently announced that it obtained National Medical Products Administration approval in China for its Perindopril Arginine and Amlodipine Besylate Tablets (III), a type 4 chemical drug for adult hypertension patients whose blood pressure is not adequately controlled by monotherapy. This regulatory clearance, which includes passing the consistency evaluation, adds a new fixed-dose combination hypertension therapy to SSY Group’s pharmaceutical portfolio and broadens its treatment options in the cardiovascular segment. Next, we will examine how this new hypertension drug approval and consistency evaluation status influences SSY Group’s broader investment narrative. AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is SSY Group's Investment Narrative?To own SSY Group, you need to believe its broadening drug portfolio can translate into steadier, higher quality earnings after a tough year of profit contraction and share price underperformance. The recent approval of the Perindopril Arginine and Amlodipine Besylate fixed-dose combination adds another cardiovascular product to a pipeline that has been steadily expanding across multiple therapeutic areas, and it marginally strengthens the near term product catalyst story rather than transforming it. The key questions now are whether this expanded line up can support the forecast profit recovery, help lift currently low returns on equity, and justify a valuation that many see as below fair value. At the same time, issues around dividend coverage, recent earnings volatility, and CEO pay versus performance remain front of mind, and this new approval does little to change those core risks. However, one key governance concern may matter more than any single new drug approval.\n\nSSY Group's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesSEHK:2005 1-Year Stock Price Chart Three fair value estimates from the Simply Wall St Community span roughly HK$3.99 to HK$6.44, underscoring how far opinions can stretch. Set that against current concerns over weaker margins and rich CEO pay, and you can see why it pays to weigh several viewpoints before deciding how SSY’s expanding portfolio might affect its longer term performance.Explore 3 other fair value estimates on SSY Group - why the stock might be worth just HK$3.99!Build Your Own SSY Group NarrativeDisagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your SSY Group research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free SSY Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate SSY Group's overall financial health at a glance.Seeking Other Investments?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 28 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.We've found 11 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602308467","isCrawlerRequest":true}